
FDA Approves Ryoncil, the First Mesenchymal Stromal Cell Therapy for Children With Steroid-Refractory Acute GvHD
8 January 2024
FDA Approves Ryoncil, the First Mesenchymal Stromal Cell Therapy for Children With Steroid-Refractory Acute GvHD
The U.S. Food and Drug Administration (FDA) has approved a groundbreaking cell-based therapy, offering renewed…